Objective: To test the hypothesis that m-opioid receptor signaling in the nucleus accumbens contributes to hedonic (over)eating and obesity. To investigate the effects of chronic m-opioid antagonism in the nucleus accumbens core or shell on intake of a palatable diet, and the development of diet-induced obesity in rats. Methods and Design: Chronic blockade of m-opioid receptor signaling in the nucleus accumbens core or shell was achieved by means of repeated injections (every 4-5 days) of the irreversible receptor antagonist b-funaltrexamine (BFNA) over 3-5 weeks. The diet consisted of either a choice of high-fat chow, chocolate-flavored Ensure and regular chow (each nutritionally complete) or regular chow only. Intake of each food item, body weight and body fat mass were monitored throughout the study. Results: The BFNA injections aimed at either the core or shell of the nucleus accumbens resulted in significantly attenuated intake of palatable diet, body weight gain and fat accretion, compared with vehicle control injections. The injection of BFNA in the core did not significantly change these parameters in chow-fed control rats. The injection of BFNA in the core and shell differentially affected intake of the two palatable food items: in the core, BFNA significantly reduced the intake of high-fat, but not of Ensure, whereas in the shell, it significantly reduced the intake of Ensure, but not of high-fat, compared with vehicle treatment. Conclusions: Endogenous m-opioid receptor signaling in the nucleus accumbens core and shell is necessary for palatable dietinduced hyperphagia and obesity to fully develop in rats. Sweet and non-sweet fatty foods may be differentially processed in subcomponents of the ventral striatum.
Introduction
A combination of increased availability of tasty, energy dense foods and sedentary behavior is thought to be the major drive in the rapidly increasing prevalence of overweight and obesity in children and adults. 1, 2 In genetically prone individuals, this 'toxic' environment can lead to overeating, obesity, diabetes and a number of other diseases of the metabolic syndrome. 3 Regulation of appetite seems to be central, as most of the known genes associated with human obesity are involved in the control of food intake. 4, 5 Thus, understanding the neural mechanisms of ingestive behavior is crucial for symptomatic treatments of this modern disease.
Eating is normally driven by metabolic need, but reinforcement by its acute pleasurable experience and the subsequent state of satisfaction makes it prone to abuse. The rewarding experience associated with eating can lead to eating in the absence of metabolic need, and has been suggested to be a form of addiction. [6] [7] [8] [9] [10] [11] The neural pathways and processes that allow rewarddriven eating to override homeostatic controls is not well understood, but probably involve a subconscious component making it partially resistant to voluntary control. Given the key roles of cortico-limbic structures in reward-driven eating and the hypothalamus in homeostatic eating, 12, 13 interactions between these two systems are likely candidates. Chemical stimulation of the nucleus accumbens has been used as a model to elicit robust, satiation-resistant eating in rats. [14] [15] [16] [17] In particular, stimulation with the m-opioid receptor agonist D-Ala2, N-Me-Phe4, Gly-ol5-enkephalin (DAMGO) induces voracious intake of palatable high-fat diet or sucrose, even in pre-satiated rodents. [15] [16] [17] [18] Although a number of brain areas are activated by opioid-induced accumbens stimulation, 16, 19 we have previously shown that activation of orexin neurons in the lateral hypothalamus and subsequent orexin-signaling in the ventral tegmental area is crucial for the expression of behavioral effects. 20 Anatomical studies have also clearly demonstrated direct and indirect projections from the nucleus accumbens to the lateral hypothalamus. [21] [22] [23] [24] Although these findings demonstrate that a m-opioid receptor-dependent, accumbens-hypothalamic pathway can acutely overpower satiation signals, its potential role in contributing to chronically rewarddriven overeating and the development of diet-induced obesity is not known.
We hypothesized that chronic suppression of m-opioid receptor signaling in the nucleus accumbens should lead to an attenuation of palatable food intake and development of obesity. b-funaltrexamine (BFNA) is a mixed short-term k-opioid receptor agonist and irreversible m-opioid receptor antagonist, 25, 26 which leads to long-lasting uncoupling of the m-opioid receptor from its G-protein. 25, 27, 28 A number of previous studies demonstrated effects of this antagonist injected either into cerebral ventricles [29] [30] [31] or directly into the nucleus accumbens 15, 27, [32] [33] [34] on food intake. Although most of these studies examined acute food intake, chronic lateral ventricular administration of BFNA for 11 days reduced food intake and body weight in rats on a palatable diet, 30 and in lean and obese Zucker rats for 7 days. 31 Furthermore, administration of BFNA directly into the nucleus accumbens selectively decreased sucrose but not chow consumption in rabbits for 4 days. 27 Therefore, in the absence of anatomically selective m-opioid receptor deletion techniques, repeated local microinjection of BFNA may be a reasonably selective tool to chronically suppress m-opioid signaling in the nucleus accumbens for more thoroughly testing its role in the development of diet-induced obesity.
The aim of our study was to assess the effects of repeated BFNA administration over several weeks to the nucleus accumbens core or shell on food intake, body weight gain and changes in body composition. To mimic the Western diet, we offered Sprague-Dawley rats a three-choice diet consisting of the nutritionally complete and medium-sweet liquid food Ensure, high-fat chow (60% of energy from fat) and regular chow.
Materials and methods

Animals
Male adult Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were housed individually in hanging stainless steel mesh cages at 22 ± 2 1C with lights on at 0700 hours and lights off at 1900 hours. Food and water were available ad libitum except where noted in Experimental protocol and measurement of food intake section below. All experimental protocols were approved by the Pennington Biomedical Research Center Institutional Animal Care and Use Committee and in compliance with National Institutes of Health and USFDA regulations.
Brain cannulation and DAMGO injections
The animals weighed B300-370 g at the time of surgery and after pretreatment with atropine (1 mg kg À1 , intraperitoneally) were anesthetized with ketamine-acepromazinexylazine cocktail (80/1.6/5.4 mg kg À1 , subcutaneously). Bilateral cannulas (24 gauge) were aimed such that injections would be made into the nucleus accumbens core (from Bregma: AP ± 1.4, LM ± 1.8, DV À5.3; n ¼ 28) or shell (AP ± 1.4, LM±1.0, DV: À5.3; n ¼ 16) using a stereotaxic apparatus and flat skull techniques, and secured to the skull using dental cement and three screws. Postoperative care included fluid replacement (saline, 5-10 ml, intraperitoneally) and analgesic treatment (carprofen, 5 mg kg À1 , intraperitoneally).
Rats were allowed to recover from the surgery for 10 days, during which they were maintained on chow, but familiarized to the taste of chocolate Ensure (Abott Nutrition, Columbus, OH, USA) and high-fat diet (D12492; Research Diets, New Brunswick, NJ, USA), and screened for their response to DAMGO. Rats were adapted to the injection procedure by two mock injections. After a 1-h pre-exposure to high-fat diet, DAMGO (D-Ala2, N-Me-Phe4, Gly-ol5enkephalin; 250 ng Â 0.5 ml À1 ), or sterile saline was injected unilaterally on separate days using 31-gauge injectors extending 2.5 mm past the cannula tip, and further intake of high-fat diet was measured for 2 h after injections. A total of 23 out of 28 rats showed increased high-fat intake of at least 3 g after DAMGO injection compared with vehicle injection and were assigned to 4 groups as described below. Mean DAMGO-induced high-fat intake was significantly higher than after vehicle and was similar for the 4 treatment groups ( Figure 6 ).
Experiment 1: BFNA injections into the nucleus accumbens core
After the recovery and adaptation period, rats exhibiting a significant ingestive response to DAMGO were randomly assigned to 4 groups. Two groups were continuously fed chow diet, one received injections of the m-opioid receptor antagonist BFNA (10 nmol Â 0.5 ml À1 on each side; Tocris, Ellisville, MO, USA; n ¼ 4), and one received vehicle (50% dimethyl sulfoxide in saline; n ¼ 5), every 4-5 days, for 36 days (eight injections plus two behavioral screening injections). The interval of 4-5 days between BFNA injections was based on in vitro 26 and in vivo studies 27 demonstrating that the m-opioid receptor antagonist activity lasts for 3-5 days.
The two other groups were switched to a three-choice diet consisting of standard chow (58% of energy from carbohydrates, 13.5% fat, 28.5% protein; # 5001 LabDiet, Purina, Richmond, IN, USA), high-fat diet (20% carbohydrate, 60% fat, 20% protein; D12492, Research Diets, New Brunswick, NJ, USA), provided in separate food hoppers, and chocolateflavored Ensure (64% carbohydrate, 21.6% fat, 14.4% protein; Abbott Ross, Columbus, OH, USA) provided in a bottle, and received either BFNA (n ¼ 7) or its vehicle (n ¼ 7), as above. All injections were administered over a 1-min period on each side using a 1-ml Hamilton syringe connected to PE-20 tubing and 30-31-gauge injectors; the injectors were left in place for 1 min to minimize backflow. This dose of BFNA has been previously shown to completely block DAMGO-induced chow intake in the nucleus accumbens. 33 Body weight and intake of chow, high-fat diet and Ensure were measured daily and corrected for spillage. Fresh Ensure was provided daily in clean bottles and spouts to prevent bacterial contamination and thickening.
Body composition (fat, lean and fluid mass) was measured weekly using nuclear magnetic resonance analysis (Bruker Minispec LF90 Time Domain NMR Analyzer; Bruker Optics, Billerica, MA, USA). Unanesthetized rats were placed into a restraining tube and measurements were made in triplicate over a period of 3 min. In addition, we also collected and weighed the inguinal, epididymal, retroperitoneal and visceral fat pads after euthanasia.
Experiment 2: BFNA injections into the nucleus accumbens shell
To avoid unnecessary tissue damage at the injection site before BFNA administration, the behavioral screening injections with saline and DAMGO were omitted. Furthermore, no chow-fed control groups were run, and rats with cannulas aimed at the nucleus accumbens shell were randomly assigned to two groups only, both exposed to the threechoice diet after the start of either BFNA (n ¼ 6) or vehicle (n ¼ 7) injections. The experiment was terminated after 22 days (five injections), when it was clear that no further separation of the body weight curves occurred. All other procedures and measures were the same as in Experiment 1.
Verification of injection sites
At the end of experiments, blue dye (0.5 ml of 1% Chicago Blue) was injected through each cannula before killing and perfusion. Brains were extracted and 30-mm thick frontal sections were examined under the microscope. Injection sites were mapped on nearest plates from the Paxinos and Watson rat stereotaxic atlas. 35 
Statistical analysis
Body weight, fat mass and food intake were analyzed using one-way or two-way analysis of variance (ANOVA) with repeated measures with adjusted Bonferroni or Newman-Keuls post hoc tests. Differences in fat pad weights between the 4 groups in Experiment 1 were analyzed using two-way ANOVA followed by Newman-Keuls post hoc tests and for the two groups in Experiment 2 with two-tailed Student's t-tests. Significance was set at Po0.05. To explicitly compare the effects of BFNA treatment in the core vs shell on intake of high-fat diet and Ensure, percent suppression of intake of either high-fat diet or Ensure based on the mean intake of the same diet with vehicle-treatment was calculated and subjected to ANOVA.
Results
BFNA reduces body weight and fat mass gain more on the palatable than on the regular chow diet As expected, rats exposed to the palatable diet gained significantly more weight and fat mass compared with chow control. In Experiment 1 (core injections), saline-injected control rats gained 114 g body weight during 37 days on the palatable diet, compared with a gain of 45 g body weight on chow (Po0.01). Body weight was significantly higher starting on day 5 in vehicle-treated, palatable diet-fed rats compared with chow-fed rats (Po0.05, Figure 1 ). Although no chow group was run in the slightly shorter Experiment 2 (shell injections), similar diet-induced weight ( þ 97 g) gain was observed over the 23-day experimental period ( Figure 1 ).
Palatable diet-induced weight gain was significantly attenuated but not abolished by repeated injections of the m-opioid receptor antagonist BFNA into the core (Figures 1, 2a and b) or shell Figures 1, 2c and d) of the nucleus accumbens. In Experiment 1 (core injections), BFNA-treated rats on the palatable diet gained 88 g body weight compared to 114 g with vehicle (À26 g). On chow, BFNA rats gained 30 g compared with 45 g with vehicle (À15 g). Two-way ANOVA revealed a significant treatment effect (P ¼ 0.014) and a significant interaction between diet and treatment (P ¼ 0.016), suggesting that BFNA reduced body weight on the palatable diet more than on the standard chow diet. Furthermore, Bonferroni-adjusted multiple comparisons revealed significant differences in body weight between BFNA and vehicle-treated rats on the palatable diet beginning on day 10 (Po0.05), but not on the chow diet ( Figure 1 ).
In Experiment 2 (shell injections), one-way repeated measures ANOVA for weight gain revealed significant treatment (Po0.01) and time (Po0.01) effects, and followup multiple comparisons showed significant differences in body weight between BFNA and vehicle-treated rats starting on day 9 (Figure 1 ).
Fat mass measured in vivo by whole body nuclear magnetic resonance relaxometry showed that in Experiment 1 (core injections), saline-injected control rats gained 45 g fat mass during 37 days on the palatable diet, compared with a gain of 14 g on chow (Po0.05; Figure 2 ). Fat mass was significantly higher starting on day 19 in vehicle-treated palatable diet-fed rats compared with chow-fed rats (Po0.05, Figure 2 ). A similar diet-induced fat mass gain ( þ 38 g) was observed over the 23-day experimental period in Experiment 2 (shell injections). In addition, measurements of individual fat pads at the end of the experiments confirm and extend whole body nuclear magnetic resonance results. Inguinal, epididymal, retroperitoneal and total fat pad weights were doubled in vehicle-treated palatable diet-fed rats compared with chow-fed rats (Figures 2b and d) .
Similarly to body weight, palatable diet-induced fat mass gain was significantly attenuated but not abolished by repeated injections of the m-opioid receptor antagonist BFNA into the core or shell of the nucleus accumbens ( Figure 2 ). In Experiment 1 (core injections), BFNA-treated rats on the palatable diet gained 32 g fat mass compared with 45 g with vehicle (À13 g). On chow, BFNA rats gained 13 g compared with 14 g with vehicle (À1 g). Although the treatment effect revealed by ANOVA was not significant (P ¼ 0.2), post hoc comparisons revealed that total fat mass and total fat pad weight in rats on the palatable diet, injected with BFNA in the nucleus accumbens core, was significantly lower than those of animals injected with vehicle (Po0.05) (Figures 2a  and b ). The BFNA effects were significant in inguinal and visceral fat pads but did not reach significance in the other fat pads.
In Experiment 2 (shell injections), BFNA-treated rats on the palatable diet gained 22 g fat mass compared with 38 g with vehicle (À17 g). Repeated measures ANOVA revealed significant effects of treatment (Po0.01) and time (Po0.01), and direct post hoc comparisons showed that total fat mass was significantly reduced by BFNA after 16 days, and both total fat mass and total fat pad weight were significantly reduced (Po0.05) at the termination of the experiment (Figures 2c and d) .
BFNA reduces total energy intake on high-fat but not regular chow diet All rats consumed more energy from Ensure than from highfat diet and less than 6% of energy from chow, regardless of treatment (Figures 3 and 4 ). Preference for Ensure was somewhat higher in Experiment 2, regardless of treatment.
With core injections, total cumulative energy intake on the three-choice palatable diet was significantly lower in Figure 1 ) significantly reduce intake of high-fat diet but not Ensure (a, b), whereas shell injections reduce intake of Ensure but not high-fat diet (d, e) ( # Po0.05, based on repeated measures analysis of variance (ANOVA) followed by Bonferroni-adjusted multiple comparisons). Total energy intake from all dietary components was also significantly reduced with BFNA injections into either core (c) or shell (f), compared with vehicle control injections.
BFNA-treated rats compared with saline-treated rats (À10%, Po0.05), whereas cumulative energy intake of the chow-fed groups was unchanged by BFNA (À2%, non significant; Figures 3 and 4 ). Direct post hoc comparisons showed significant BFNA-induced decreases in total palatable diet intake starting on day 22 (Figure 3c ).
With shell injections, BFNA also significantly reduced total cumulative palatable diet intake (À16%, Po0.05; Figures 3  and 4 ). Direct post hoc comparisons showed significant BFNAinduced decreases in total palatable diet intake starting on day 10 (Figure 3f ).
BFNA in the shell and core differentially affect intake of Ensure and high-fat diet When the individual components of the three-choice palatable diet are examined, we observed differential effects of BFNA in the nucleus accumbens core versus the shell. BFNA injected into the core significantly reduced the intake of high-fat diet, but not of Ensure, whereas BFNA injected into the shell significantly reduced the intake of Ensure, but not of high-fat diet when compared with the respective vehicle control groups. Using separate repeated measure ANOVA analyses, we were able to show that cumulative intake of high-fat diet was significantly lower (Po0.05) with BFNA treatment of the core compared with vehicle treatment on days 23-37, and that cumulative intake of Ensure was significantly lower (Po0.05) with BFNA treatment of the shell on days 15-19 ( Figure 3 ). Furthermore, explicit comparison of core and shell using percent suppression of intake of either high-fat diet or Ensure based on the mean intake of the same diet with vehicle treatment yielded a significant interaction between diet and injection site (F 1,25 ¼ 12.85; Po0.002), and significant effects of diet within core (t ¼ 2.45; P ¼ 0.023) and diet within shell (t ¼ 2.61; P ¼ 0.016; Figure 4 ).
Nucleus accumbens core and shell injection sites
Owing to problems with tissue processing, not all core injection sites were histologically verified. The successfully verified sites showed the expected scatter around the intended location either 1000 mm (shell) or 1800 mm (core) lateral to the midline ( Figure 5 ). Although some sites were up to 400 mm off the intended location, the 500-nl volume of drug injected (occupying a pore space of 41,200 mm diameter 36 ) was more than enough to affect the intended location. This is also supported by the functional verification with DAMGO injections before the chronic BFNA/vehicle treatments. Rats were only assigned to the treatment groups if their average intake with left and right DAMGO administration was at least 3 g higher than after vehicle administration ( Figure 6 ).
To assure that effects of BFNA injected into the core were similar for the rats with histologically verified and nonverified cannula placements, we analyzed all dependent variables for only the rats with histologically verified cannula placements. This analysis showed very similar effects for body weight gain, fat mass gain, total food intake and differential Ensure vs high-fat intake. Furthermore, in the functional verification test, the average DAMGOinduced high-fat intake was not different for the histologically verified and non-verified rats.
Two rats with injections in the most caudal portion of the nucleus accumbens ( Figure 5) were excluded from analysis. They both received BFNA treatment, but behaved like salinetreated rats in all measures.
Discussion
The nucleus accumbens is recognized as a key brain area involved in reward processing, and here we show that chronic suppression of endogenous m-opioid receptor signaling in the nucleus accumbens significantly attenuates the development of diet-induced obesity by reducing the intake of palatable preferred foods in Sprague-Dawley rats. As BFNA has some short-term k-agonist activity, 25, 26, 29 we cannot rule out the co-involvement of k-opioid receptor signaling in the observed effects. However, the continuous m-opioid receptor antagonism is likely to have the dominant role, with only minor effects of the brief k-agonist stimulation every 4-5 days. The findings suggest that m-opioid receptor signaling in the nucleus accumbens significantly contributes to the hyperphagia, body weight gain and body fat accretion observed when rodents are exposed to a palatable cafeteria diet. We chose two food items that are both very palatable to rats but also very different. High-fat chow is a creamy, nonsweet solid food, whereas Ensure is a medium sweet (8% sugar) creamy liquid. On average, Ensure was slightly preferred over the high-fat chow, and both were highly preferred over regular laboratory chow (Figure 4a ). Thus, the three-choice diet is more closely mimicking human food intake than a single item diet.
However, the relatively mild hypophagia and only partial prevention of the obesogenic effect of the palatable diet clearly show that this is only one mechanism contributing to diet-induced obesity. Contributions of m-opioid receptormediated mechanisms in other areas of the brain, and non-m-opioid receptor-mediated mechanisms in the nucleus accumbens and other brain areas are probably also involved. There is an extensive literature on opioids and food intake, but most studies address acute rather than chronic effects. We will first discuss some of these relevant earlier observations before focusing on the differential effects with core and shell injections, and the effects on body weight and fat mass.
Opioids, food intake and obesity Systemic administration of opioid agonists and antagonists increases and decreases food intake, respectively, suggesting BFNA (n = 4) Figure 6 Functional verification of accumbens core injection sites. Two-hour high-fat intake of rats with bilateral cannulas aimed at either the core or shell of the nucleus accumbens and assigned to either chronic vehicle or BFNAtreatment. Intake for left and right cannula injections was tested separately and the mean intake from both sides was used for each rat. BFNA stimulated high-fat intake to a similar extent in all 4 groups. Figure 5 Histological verification of nucleus accumbens injection sites. Location of injection sites aimed at the nucleus accumbens core (left panel) and shell (right panel) superimposed on images from a stereotaxic atlas. 35 Note that rats with shell injections were only tested with palatable food. Two rats with bilateral injection cannulas located in the caudal shell (gray triangles) and injected with b-funaltrexamine (BFNA) did not show reduced body weight and food intake and were not included in the analysis.
Accumbens MOR contributes to diet-induced obesity NR Lenard et al that the opioid system has a role in the regulation of ingestive behavior. For example, repeated systemic injections of the prototypical m-opioid receptor agonist, morphine, increases food intake, 37 whereas systemic injection of the m-opioid receptor antagonist BFNA, 38 and the non-selective opioid receptor antagonist, naltrexone, 39 reduce food intake. 40 In addition, daily oral treatment with a nonselective opioid receptor antagonist (LY255582), reduced food intake throughout the 16-week treatment period and pair-feeding recapitulated much of the decreased body weight and adiposity seen in drug-treated rats. 41 Opioid receptors expressed in several brain regions (nucleus of the solitary tract, 42 parabrachial nucleus, 43 arcuate nucleus, 44, 45 paraventricular nucleus of the hypothalamus 46 and nucleus accumbens 47, 48 ) probably mediate the effects of systemically administered opioids.
Surprisingly, the m-opioid receptor-deficient mouse shows only a subtle, and sexually dimorphic, phenotype regarding food intake and body weight/adiposity. Hypophagia is not or only variably observed, but when challenged with palatable high-fat diets, knockout mice do resist development of obesity compared with wild-type controls. 49, 50 These findings suggest that m-opioid receptor signaling, perhaps in peripheral organs, might also have suppressive effects on food intake and/or stimulatory effects on fat oxidation and energy expenditure, and demonstrate the need for more localized manipulations of m-opioid receptor signaling.
Chronic BFNA treatment of the nucleus accumbens delays development of diet-induced obesity BFNA-treatment, centered around the core or shell of the nucleus accumbens, significantly attenuated body weight gain and body fat accretion on the palatable diet. In contrast, BFNA treatment of the core had a smaller and nonsignificant effect on body weight gain and no effect on fat mass gain in chow-fed control groups, consistent with the many reports demonstrating more or less selective modulation of 'hedonic' eating by opioids. 18, 38, 51, 52 We based our study on an earlier observation in rabbits, showing that a single injection of BFNA into the nucleus accumbens shell uncoupled the m-opioid receptor from its G-protein and selectively decreased daily 4-h sucrose, but not 20-h chow, intake for up to 4 days. 27 As sucrose was only offered for a short period every day, no decrease in body weight was observed. Here, we show that chronic (3-5 weeks) suppression of m-opioid receptor signaling in the nucleus accumbens with BFNA reduces the development of obesity when rats have continuous access to a variety of palatable foods.
Two studies have examined the effects of chronic intraventricular administration of BFNA on the development of diet-induced obesity 30 and body weight in obese Zucker rats, 31 but the observation periods were limited to 11 and 7 days and body composition was not measured. In both models, BFNA significantly reduced body weight compared with vehicle treatment. Our results suggest that, at least, one of the sites necessary for these chronic weight-lowering effects of BFNA is the area of the nucleus accumbens, and that endogenous m-opioid receptor signaling in this nucleus is required for the full extent of diet-induced obesity to develop.
Although it is clear that decreased energy intake caused some of the observed changes in body weight and composition (see below), changes in energy expenditure could have contributed to the loss of body weight and fat mass. We did not notice any major changes in physical activity levels during the treatment periods. Locomotor activity after BFNA injections into the nucleus accumbens has not been reported, but injecting BFNA into the lateral ventricle reduced locomotor activity for two days after injection. 53 If BFNA injections into the nucleus accumbens would similarly decrease locomotor activity, the reduced weight gain observed in our experiments would be the more impressive, as reduced locomotor activity would lead to increased weight gain. However, measurement of energy expenditure, substrate oxidation and locomotor activity will be necessary to determine the relative contribution of energy intake and expenditure on body weight and adiposity.
BFNA reduces total intake and differentially affects intake of high-fat diet and Ensure in the core and shell We selected a three-choice diet composed of high-fat chow (60% energy), chocolate-flavored Ensure and standard chow, all nutritionally complete, as a palatable diet to induce obesity. Normal Sprague-Dawley rats can be divided into two populations: one resistant and one susceptible to diet-induced obesity on a high-energy diet. However, the addition of Ensure to the high-fat diet makes most Sprague-Dawley rats obese. 54 It has been shown that intermittent access to sucrose but not high-fat diet can produce addictive-type behavior in rats. 8 Therefore, our three-choice diet is more likely to mimic all aspects of hedonic appetite mechanisms also found in humans, than single high-fat diet.
Although core injections of BFNA selectively reduced intake of high-fat diet, shell injections selectively reduced intake of Ensure compared with vehicle injections. Unfortunately, we screened for DAMGO effects only with core injections, but the effect on high-fat intake is in agreement with a study demonstrating that core injections of DAMGO more robustly increased high-fat intake compared with shell injections. 55 Similarly, the selective effect of shell injections on Ensure (a sweet tasting liquid) intake is in agreement with studies examining the effect of DAMGO on sucrose solutionsFDAMGO robustly increased sucrose ingestion when injected into the ventral shell of the nucleus accumbens, although no a priori attempt to restrict injections to either the core or the shell of the accumbens was made. 15 Furthermore, DAMGO, when administered into a 1-mm 3 'hotspot' of the nucleus accumbens, robustly increases the affective responses to sucrose ingestion, an effect that is regarded as increased 'liking' of sucrose. 56 Although our injection sites do not exactly overlap this 'hotspot' for sucrose affective responses, they are close to sites that increase sucrose ingestion. 56 A limitation of our study is the lack of histological verification of a subset of injection cannulas aimed at the core. However, all cannulas were functionally verified by demonstrating a robust high-fat feeding response to the injection of DAMGO. Furthermore, analysis of the major outcome measures in only those animals with histologically verified cannulas showed very similar effects of BFNA observed in the complete set of animals.
Conclusions
By chronically blocking endogenous signaling, these studies suggest that m-opioid receptors in the nucleus accumbens shell and core, at least, partially mediate the hyperphagia and development of obesity when exposed to a palatable diet. The findings corroborate some studies demonstrating reduced susceptibility to diet-induced obesity in Oprm-1 knockout mice and with chronic systemic administration of opioid receptor antagonists in rats, and point to the nucleus accumbens as an important site of action. The results show that reduction of palatable food intake is, at least, one mechanism leading to reduced weight gain, but changes in energy expenditure and nutrient partitioning cannot be ruled out.
Given the wide distribution of m-opioid receptors in the brain and periphery, it will be necessary to use tissueselective loss-of-function approaches to further analyze the relative contribution of various brain areas and peripheral mechanisms. Understanding the role of m-opioid receptor signaling in stimulation of palatable food intake may lead to new targets for drug development.
